SpyGlass Pharma, Inc. (SGP)

Market Cap	753.31M
Revenue (ttm)	n/a
Net Income	-39.87M
EPS	-17.98
Shares Out	33.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,374
Open	24.63
Previous Close	25.20
Day's Range	21.29 - 24.63
52-Week Range	20.16 - 32.44
Beta	n/a
Analysts	Strong Buy
Price Target	45.00 (+99.03%)
Earnings Date	Mar 26, 2026

About SGP

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which comprises novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, In...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2026
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: SGP
• Website: https://www.spyglasspharma.com

Analyst Summary

According to 5 analysts, the average rating for SGP stock is "Strong Buy." The 12-month stock price target is $45.0, which is an increase of 99.03% from the latest price.

Price Target

$45.0

(99.03% upside)

Analyst Consensus: Strong Buy